Lebwohl M, Bachelez H, Gordon K, Wu T, Chen M, Kaplan B, Papp K. Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study. J of Skin [Internet]. 2023 Nov. 13 [cited 2024 Jul. 3];7(6):s258. Available from: https://jofskin.org/33014/index.php/skin/article/view/2428